Solid Biosciences Receives FDA Fast Track Designation for Gene Therapy Targeting CPVT
Thursday, July 24, 2025
Solid Biosciences Inc. has received Fast Track designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, SGT-501.
CPVT affects approximately 1 in 10,000 people globally. It typically emerges in childhood or adolescence and is often misdiagnosed. The condition is linked to mutations in the RYR2 and CASQ2 genes, leading to abnormal calcium handling in heart cells. This can cause dangerous arrhythmias during physical activity or emotional stress, with symptoms ranging from fainting and seizures to sudden cardiac arrest.
Currently, no approved treatments directly address the underlying genetic causes of CPVT.
SGT-501 is an adeno-associated virus (AAV)-based gene therapy designed to deliver a functional, full-length, codon-optimised version of the human cardiac calsequestrin (CASQ2) gene directly to heart muscle cells. This approach is aimed at correcting the calcium handling problems and abnormal heart rhythms seen in individuals with CPVT, particularly those caused by RYR2 gene instability.
SGT-501 also received Investigational New Drug (IND) clearance from the FDA and Clinical Trial Application (CTA) approval from Health Canada on 8 July 2025. A Phase 1b trial is expected to begin in the final quarter of 2025. This first-in-human study will assess the safety, tolerability, and potential effectiveness of the gene therapy in individuals living with CPVT.
The therapy is being developed to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare and potentially life-threatening inherited heart condition.
The Fast Track designation is intended to support the development of treatments for serious conditions with unmet medical needs.
It allows for more frequent communication with the FDA and may lead to a faster review process.
Source: globenewswire.com
